As adoptively transferred natural killer (NK) cells possess a shorter lifetime, are associated with fewer side effects, and hold an intrinsic CAR-independent killing capacity against AML, CD33-CAR-NK cells constitute a promising alternative [16–19]. The gene discussed is CD33; the disease is acute myeloid leukemia.